a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

被引：0
作者：
Daver, Naval
Assi, Rita
Garcia-Manero, Guillermo
Ravandi, Farhad
Borthakur, Gautam
Jabbour, Elias J.
DiNardo, Courtney D.
Kadia, Tapan
Ning, Jing
Gonzalez, Graciela Nogueras
Pierce, Sherry
Kelly, Mary
Zhang, Weiguo
Gombos, Dan
Kornblau, Steven
Konopleva, Marina
Cortes, Jorge E.
Kantarjian, Hagop M.
Andreeff, Michael
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1344
引用
收藏
页数：3
相关论文
共 50 条
[21]   A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia [J].
Qi, Junyuan ;
Song, Lin ;
Wei, Xudong ;
Zhai, Zhimin ;
Wang, Anyou ;
Jiang, Daozi ;
Liang, Yang ;
Li, Fei ;
Jiang, Zhongxing ;
Zhang, Xuejun ;
Guo, Qunyi ;
Jing, Hongmei ;
Xu, Yajing ;
Tong, Xiangmin ;
Wang, Jianxiang .
BLOOD, 2023, 142
[22]   PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY [J].
Cella, D. ;
Ritchie, E. ;
Fabbiano, F. ;
Pigneux, A. ;
Kanda, Y. ;
Ivanescu, C. ;
Pandya, B. ;
Shah, M., V .
VALUE IN HEALTH, 2019, 22 :S531-S531
[23]   Preliminary safety, efficacy and molecular characterization of emavusertib (CA-4948) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation (FLT3m). [J].
Winer, Eric S. ;
Verma, Amit ;
Groepper, Stefanie ;
Gotze, Katharina S. ;
Abaza, Yasmin ;
Mikesch, Jan-Henrik ;
Choudhary, Gaurav S. ;
Masciarelli, Alyssa ;
Zhao, Wanying ;
Gallagher, Cole ;
Von Roemeling, Reinhard W. ;
DeAngelo, Daniel J. .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[24]   The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study [J].
Cella, David ;
Ritchie, Ellen K. ;
Fabbiano, Francesco ;
Pigneux, Arnaud ;
Kanda, Yoshinobu ;
Ivanescu, Cristina ;
Pandya, Bhavik J. ;
Shah, Manasee V. .
BLOOD, 2019, 134
[25]   A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML) [J].
Daver, Naval G. ;
Zhang, Weiguo ;
Graydon, Richard ;
Dawra, Vikas K. ;
Xie, Jingdong ;
Kumar, Prasanna ;
Andreeff, Michael .
BLOOD, 2019, 134
[26]   Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial [J].
Perl, Alexander E. ;
Martinelli, Giovanni ;
Cortes, Jorge E. ;
Neubauer, Andreas ;
Berman, Ellin ;
Paolini, Stefania ;
Montesinos, Pau ;
Baer, Maria R. ;
Larson, Richard A. ;
Ustun, Celalettin ;
Fabbiano, Francesco ;
Di Stasi, Antonio ;
Stuart, Robert ;
Olin, Rebecca ;
Kasner, Margaret ;
Ciceri, Fabio ;
Chou, Wen-Chien ;
Podoltsev, Nikolai ;
Recher, Christian ;
Yokoyama, Hisayuki ;
Hosono, Naoko ;
Yoon, Sung-Soo ;
Lee, Je-Hwan ;
Pardee, Timothy ;
Fathi, Amir T. ;
Liu, Chaofeng ;
Liu, Xuan ;
Bahceci, Erkut ;
Levis, Mark J. .
CANCER RESEARCH, 2019, 79 (13)
[27]   Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial [J].
Cortes, Jorge E. ;
Khaled, Samer K. ;
Martinelli, Giovanni ;
Perl, Alexander E. ;
Ganguly, Siddhartha ;
Russell, Nigel H. ;
Kramer, Alwin ;
Dombret, Herve ;
Hogge, Donna ;
Jonas, Brian A. ;
Leung, Anskar Y. -H. ;
Mehta, Priyanka ;
Montesinos, Pau ;
Radsak, Markus P. ;
Sica, Simona ;
Arunachalam, Meena ;
Holmes, Melissa ;
Kobayashi, Ken ;
Namuyinga, Ruth ;
Ge, Nanxiang ;
Yver, Antoine ;
Zhang, Yufen ;
Levis, Mark J. .
BLOOD, 2018, 132
[28]   A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) [J].
Cashen, Amanda F. ;
Liu, Hongtao ;
Al Malki, Monzr M. ;
Zeidner, Joshua F. ;
Foster, Matthew C. ;
Pannunzio, Angela ;
Ramsey, Brett ;
Baughman, Jan ;
Muth, John ;
Bakkacha, Ouiam ;
McNulty, Eileen ;
Jacobs, Kenneth ;
Davidson-Moncada, Jan K. ;
Wei, Andrew H. .
BLOOD, 2022, 140 :12740-12741
[29]   A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) [J].
Erba, Harry P. ;
Oluwole, Olalekan O. ;
Bixby, Dale ;
Rampal, Raajit K. ;
Fathi, Amir T. ;
Paliwal, Prashni ;
Jin, Jin ;
Inoue, Ai ;
Daver, Naval .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 :S311-S312
[30]   Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia [J].
McMahon, Christine M. ;
Canaani, Jonathan ;
Rea, Bryan ;
Sargent, Rachel Lynn ;
Morrissette, Jennifer J. D. ;
Lieberman, David B. ;
Watt, Christopher ;
Schwartz, Gregory W. ;
Faryabi, Robert B. ;
Ferng, Timothy T. ;
Shah, Neil P. ;
Smith, Catherine C. ;
Carroll, Martin ;
Perl, Alexander E. .
BLOOD, 2017, 130
12345